Deals
Stada’s Independence in the Crosshairs on Buyout Speculation
- Company said to have attracted attention from PE firms
- Drugmaker’s stock has climbed almost 20 percent since May
This article is for subscribers only.
Stada Arzneimittel AG’s time as an independent drugmaker selling copies of medicines like Viagra may be drawing to a close.
The German company has attracted interest from several private equity firms including Permira, CVC Capital Partners and Bain Capital, according to people familiar with the matter. Buyout firms have been studying the feasibility of a takeover with potential advisers, though deliberations are at an early stage, the people said, asking not to be identified as the discussions are confidential. Rival generics companies have also informally looked at Stada, the people said.